CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Sample collectionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug1043 Helmet Continuous Positive Airway Pressure (CPAP) Wiki 0.71
drug2131 SARS-CoV-2 PCR Wiki 0.71
drug1054 High Flow Nasal Oxygen (HFNO) Wiki 0.71

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D011024 Pneumonia, Viral NIH 0.09
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06
D011014 Pneumonia NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.04

There are 2 clinical trials

Clinical Trials

1 Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals

The purpose of this study is to learn more about infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some people know this virus by the name "coronavirus." It can cause the disease called COVID-19. The information gained from the study will be used to help develop better tests for SARS-CoV-2 infection and COVID-19 disease and may help in developing future vaccines and treatments by allowing researchers to determine the difference between the body's immune response to natural SARS-CoV-2 infection and immunization with a SARS-CoV-2 vaccine.

NCT04403880 SARS-CoV-2 COVID-19 Other: Sample collection

Primary Outcomes

Description: Measured by peptide microarray

Measure: Humoral responses to peptide antigens derived from SARS-CoV-2 structural proteins and regions of the spike protein not present in vaccines

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by binding antibody multiplex assay (BAMA)

Measure: SARS-CoV-2-specific antibody binding response rate

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by binding antibody multiplex assay (BAMA)

Measure: SARS-CoV-2-specific antibody binding response magnitude

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by binding antibody multiplex assay (BAMA)

Measure: SARS-CoV-2-specific antibody binding response epitope specificity

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by neutralizing antibody assay (NAb)

Measure: SARS-CoV-2-specific antibody neutralization response rate

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by neutralizing antibody assay (NAb)

Measure: SARS-CoV-2-specific antibody neutralization response magnitude

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by neutralizing antibody assay (NAb)

Measure: SARS-CoV-2-specific antibody neutralization response epitope specificity

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by antibody-dependent cellular cytotoxicity assay (ADCC)

Measure: SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response rate

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by antibody-dependent cellular cytotoxicity assay (ADCC)

Measure: SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response magnitude

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by antibody-dependent cellular cytotoxicity assay (ADCC)

Measure: SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response epitope specificity

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by flow cytometry

Measure: SARS-CoV-2-specific CD4+ and CD8+ T cell responses

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by flow cytometry

Measure: SARS-CoV-2-specific CD4+ and CD8+ T cell response rate

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by flow cytometry

Measure: SARS-CoV-2-specific CD4+ and CD8+ T cell response magnitude

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by flow cytometry

Measure: SARS-CoV-2-specific CD4+ and CD8+ T cell response functional profiling

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by phenotyping and monoclonal antibody isolation

Measure: SARS-CoV-2-specific memory B cell characterization

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Tabulated overall and by group

Measure: SARS-CoV-2-specific infection presentation, including clinical course, along with demographics and corresponding medical history of participants

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Secondary Outcomes

Description: Measured by real-time reverse transcription polymerase chain reaction (RT-PCR) assay

Measure: Detection of viral RNA in nasopharyngeal or nasal swab samples

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by binding antibody multiplex assay (BAMA)

Measure: Response rate of SARS-CoV-2-specific binding antibodies in nasal samples

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

Description: Measured by binding antibody multiplex assay (BAMA)

Measure: Response magnitude of SARS-CoV-2-specific binding antibodies in nasal samples

Time: Measured through participant's last visit at Month 0, 2, 4, or 12

2 A Prospective Study of Acute Immune Responses to SARSCoV-2 Infection

The purpose of this study is to learn more about the acute response to infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some people know this virus by the name "coronavirus." It can cause the disease called COVID-19. The information gained from the study can be used to help develop better tests for SARS-CoV-2 infection and COVID-19 disease and may help in developing future vaccines, other prevention strategies, and treatments.

NCT04431414 SARS-CoV-2 COVID-19 Other: Sample collection

Primary Outcomes

Description: Characterized using fluorescently labeled recombinant proteins in combination with a flow cytometry phenotyping panel

Measure: Response rate of SARS-CoV-2-specific B cells in peripheral blood samples

Time: Measured through day 14

Description: Characterized using fluorescently labeled recombinant proteins in combination with a flow cytometry phenotyping panel

Measure: Magnitude of SARS-CoV-2-specific B cells in peripheral blood samples

Time: Measured through day 14

Description: Characterized using fluorescently labeled recombinant proteins in combination with a flow cytometry phenotyping panel

Measure: Phenotypic characterization of SARS-CoV-2-specific B cells in peripheral blood samples

Time: Measured through day 14

Description: Measured by binding antibody multiplex assay (BAMA)

Measure: Response rate of SARS-CoV-2-specific antibody binding in serum samples

Time: Measured through day 28

Description: Measured by neutralizing antibody assay (nAb)

Measure: Response rate of SARS-CoV-2-specific neutralizing antibodies in serum samples

Time: Measured through day 28

Description: Measured by binding antibody multiplex assay (BAMA)

Measure: Magnitude of SARS-CoV-2-specific antibody binding antibodies in serum samples

Time: Measured through day 28

Description: Measured by neutralizing antibody assay (nAb)

Measure: Magnitude of SARS-CoV-2-specific neutralizing antibodies in serum samples

Time: Measured through day 28

Description: Measured by binding antibody multiplex assay (BAMA)

Measure: Response rate of SARS-CoV-2-specific binding antibodies in nasal wash samples

Time: Measured through day 28

Description: Measured by binding antibody multiplex assay (BAMA)

Measure: Magnitude of SARS-CoV-2-specific binding antibodies in nasal wash samples

Time: Measured through day 28

Description: Measured by flow cytometry

Measure: Frequency of leukocyte populations in peripheral blood

Time: Measured through day 14

Description: Measured by gene expression analysis by RNA sequencing, real-time PCR, single-cell proteogenomic profiling

Measure: Transcriptional profiles of peripheral blood leukocytes

Time: Measured through day 14

Description: Measured by multiplexed protein detection assays and/or enzyme-linked immunosorbent assays (ELISA)

Measure: Concentration of serum cytokines and other soluble factors

Time: Measured through day 28

Description: Measured by flow cytometry

Measure: Response rate of SARS-CoV-2-specific CD4+ and CD8+ T cells

Time: Measured through day 28

Description: Measured by flow cytometry

Measure: Magnitude of SARS-CoV-2-specific CD4+ and CD8+ T cells

Time: Measured through day 28

Description: Measured by flow cytometry

Measure: Functional profiling, including intracellular cytokine staining, of SARS-CoV-2-specific CD4+ and CD8+ T cells

Time: Measured through day 28

Secondary Outcomes

Description: Measured by extraction of nucleic acid for analysis of microorganism RNA or DNA by qPCR and/or amplicon- or metagenomics-sequencing methods and subsequent gene and taxa-level bioinformatics analyses

Measure: Quantitation of viral RNA in nasal swabs

Time: Measured through day 28

No related HPO nodes (Using clinical trials)